2020 On-site Forms Industry and Scientific Advisory Board
2020 On-site has formed an Industry and Scientific Advisory Board (IASAB) that will steer its initiatives by gathering insights, sharing ideas, and debating critical business concepts.
The board’s seven members will gather quarterly to identify patient needs, product opportunities and market challenges associated with the provision of vision-related assessments for clinical trials and safety surveillance programs.
On the board are Ms. Jeanne Taylor Hecht, IASAB chair and the founder and CEO of JTH Consulting, LLC; Rajat Agrawal MD, MS, CEO and president of Retina Global; Jeffrey S. Heier, MD, director of the vitreoretinal service and retina research at Ophthalmic Consultants of Boston; Peter K. Kaiser, MD, Chaney Family Endowed Chair in Ophthalmology Research and a professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine; Beth Marsh, vice president of North America Sales and Marketing, Ophthalmology, for Apellis Pharmaceuticals; Jason Menzo, Chief Operating Officer of Foundation Fighting Blindness; and Adam Ramsey, OD, an optometrist and owner of Socialite Vision.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
